Search

Find exactly what you’re looking for.
Search

Service
Showing 1-20 of 81 results

Saul Ewing LLP will be a Bronze Sponsor at the 7th Annual LF Dealmakers Forum in NYC, September 17-19, 2024. Based on the success of IP Dealmakers – and our experience examining complex markets and bringing together influential groups in the converging fields of legal and finance – we launched the...

Introduction In May 2022, a jury in the Circuit Court for Fairfax County, Virginia awarded Appian Corp. (Appian) in excess of $2 billion in damages from Pegasystems, Inc. (Pegasystems) for misappropriating Appian’s trade secrets in violation of the Virginia Uniform Trade Secrets Act (VUTSA). This...

Saul Ewing LLP is proud to announce that Charles M. Lizza, Vice Chair of the firm’s Litigation Department, was named to the NJBIZ 2024 Law Power 50 list. This is the sixth year in a row that Mr. Lizza has been included on this list of the state's top lawyers. Professionals are selected for the list...

In a conversational 30-minute forum over Zoom, Saul Ewing attorneys hosted a monthly series discussing emerging industry developments and common issues that cannabis businesses face today. Interested in the full series? Learn more about additional dates and topics. For questions, please contact Mary...

Introduction On June 18, 2024, the Federal Trade Commission (“FTC”) unanimously agreed to submit a comment supporting a recent proposed U.S. Patent and Trademark Office (“PTO”) rule that would mandate the disclosure of all settlement agreements made between parties appearing before the Patent Trial...

Lawyers Only: Making Litigation Funding Better What are the best practices for firms to seek working capital? How do firms recommend funders for their clients? How are law firms contemplating using funding or investment for cases after filing? How does one navigating the ethical, privilege...

Litigation Risk Insurance; New Coverages; Risk Solutions; and Nuclear Claims? Litigation risk insurance, which for the most part, insures against adverse judgments or assists in preserving judgments, has become popular in the last few years. What is litigation risk insurance? How is it underwritten...

Breaking (free from) the Bank: Cannabis Litigation Finance This panel provides an overview of litigation finance, explores unique aspects of cannabis litigation that make cannabis litigation finance necessary, and provides resources for cannabis attorneys and their clients as they explore litigation...

January 26, 2024 - With AI poised to reshape the practice of law and businesses in every industry, Saul Ewing is pleased to partner with the ABA’s Intellectual Property Litigation Committee in forming the AI Subcommittee. The AI Subcommittee will monitor legal and technological developments in this...

Panel 4: The Connections Between Insurance and Litigation Funding Join Partner Brian Michalek and the University of Chicago Center on Law and Finance , in sponsorship with Burford Capital and Alliant, at the 2023 Chicago Conference on Litigation Finance. This conference will explore the policy...

Saul Ewing’s Casey Grabenstein and Andrew Schwerin write that courts are divided on whether plaintiff bias justifies discovery about litigation funding. They argue litigation funding wouldn’t often create a conflict of interest for a plaintiff.

Contingent Liability Insurance Demystified Partner Brian Michalek will speak on a panel during the 2023 Transaction Solutions Symposium. More information to come.

Hot Topics in eDiscovery Join Associate Christie McGuiness and Director of Litigation Support Services Ricky Brooman during the upcoming SDNY Chapter of the Federal Bar Association IN PERSON discussion of eDiscovery featuring an esteemed panel of speakers. Following the discussion, attendees are...

​On May 18, 2023, the Supreme Court unanimously affirmed the Federal Circuit's decision, Amgen Inc. v. Sanofi, 987 F.3d 1080 (Fed. Cir. 2021), that the claims of two of Amgen's patents were invalid for lack enablement. The involved patents, US 8,829,165 and US 8,859,741, are directed to monoclonal...

For More Information
Contact us